Background: Province-level evidence on the implementation of population-based HPV screening in eastern Türkiye remains limited. This study aimed to describe screening activity relative to the programme-defined target population, HPV test positivity, recorded genotype patterns, histopathological diagnoses, and available follow-up information within the cervical cancer screening programme in Van Province. Methods: This retrospective, record-based programme evaluation used aggregated programme data from 2022 through the first two months of 2026 and individual-level records for HPV-positive women from 2023–2025. Annual screening activity ratios were calculated using programme-defined target populations. Age and recorded genotype distributions were described among HPV-positive women. Histopathological diagnoses and referral-related information were reported as available programme records because individual-level linkage and complete pathway denominators were unavailable. Temporal change in programme HPV test positivity was assessed using the Cochran-Armitage trend test. Results: Across the study periods, annual screening counts summed to 94,123 records, with 2,078 HPV-positive results (2.21%). The screening activity ratio increased from 17.1% in 2022 to 95.5% in 2024 and decreased to 67.9% in 2025. Observed programme HPV test positivity declined from 3.17% in 2022 to 1.80% in 2025 (p for trend < 0.001). Among 1,810 HPV-positive women with individual-level data, the mean age was 44.5 years. HPV16 was the most frequently recorded specific genotype (36.4%), HPV16 and/or HPV18 was recorded in 43.8%, and at least one recorded oncogenic genotype targeted by the nine-valent vaccine was identified in 55.4%. Multiple specifically identified HPV genotypes were recorded in 16.5%. Programme records contained 394 histopathological diagnoses during 2023–2025, including three invasive cervical cancer records. Available follow-up data did not permit calculation of referral, hospital attendance, colposcopy, biopsy, or treatment completion rates. Conclusions: HPV screening activity in Van varied substantially across years, while observed programme test positivity declined during 2022–2025; this decline should not be interpreted as evidence of reduced population HPV prevalence. Recorded genotype findings were dominated by HPV16, but variation in type-specific reporting limits temporal interpretation. Improved standardization of genotype reporting and individual-level linkage across screening, referral, diagnosis, histopathology, and treatment would strengthen programme monitoring.